Compare · EPRX vs NVCN
EPRX vs NVCN
Side-by-side comparison of Eupraxia Pharmaceuticals Inc. (EPRX) and Neovasc Inc. (NVCN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EPRX and NVCN operate in Pharmaceuticals and Biotechnology (Health Care), so they compete in similar markets.
- EPRX is the larger of the two at $446.2M, about 16.0x NVCN ($27.8M).
- EPRX has hit the wire 7 times in the past 4 weeks while NVCN has been quiet.
- EPRX has more recent analyst coverage (9 ratings vs 0 for NVCN).
- Company
- Eupraxia Pharmaceuticals Inc.
- Neovasc Inc.
- Price
- -
- -
- Market cap
- $446.2M
- $27.8M
- 1M return
- -21.28%
- -
- 1Y return
- +13.68%
- -
- Industry
- Pharmaceuticals and Biotechnology
- Pharmaceuticals and Biotechnology
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 7
- 0
- Recent ratings
- 9
- 0
NVCN
Neovasc Inc.
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices for cardiovascular marketplace in Europe, Canada, the United States, and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Latest EPRX
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
- Wedbush initiated coverage on Eupraxia Pharmaceuticals with a new price target
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
- SEC Form SUPPL filed by Eupraxia Pharmaceuticals Inc.
Latest NVCN
- Volato Announces Changes to Board Composition
- SEC Form EFFECT filed by Neovasc Inc.
- SEC Form 15F-12B filed by Neovasc Inc.
- SEC Form 6-K filed by Neovasc Inc.
- SEC Form 6-K filed by Neovasc Inc.
- SEC Form RW filed by Neovasc Inc.
- SEC Form F-10POS filed by Neovasc Inc.
- SEC Form POS AM filed by Neovasc Inc.
- SEC Form S-8 POS filed by Neovasc Inc.
- SEC Form 25-NSE filed by Neovasc Inc.